Menu

August 22, 2023

News
Media
Awards
Contact
News
Media Resources
Awards
Contact
August 22, 2023
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization

2026

2025

2024

2023

2022

2021

2020

2019

August 22, 2023
Highlights of Asieris Pharmaceuticals 2023 Semi-Annual Report
April 17, 2026
Asieris Pharmaceuticals Releases 2025 Annual Report：Flagship Product Approval Marks Inflection Point; Commercialization 2.0 Drives Growth
August 22, 2023
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization
August 22, 2023
Highlights of Asieris Pharmaceuticals 2023 Semi-Annual Report
March 3, 2026
Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
August 22, 2023
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization
August 22, 2023
Highlights of Asieris Pharmaceuticals 2023 Semi-Annual Report
January 8, 2026
Asieris Enrolls First Patient in China in Phase I Clinical Trial of APL-2401 for Patients with FGFR2/3-Driven Advanced Solid Tumors
August 22, 2023
Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization